Patients and Profitability: Why the Most Successful Pharmaceutical Companies Never Choose Between Them

For most of my career I sat in rooms where the same question eventually surfaced. Are we optimizing for patients, or are we optimizing for the business? I asked it myself for years before I understood that the question was the problem.

Patient outcomes and commercial profitability are not opposing forces. They are two readings of the same discipline. Every durable commercial win in this industry traces back to a real improvement in the patient journey, and every real improvement that never becomes commercially sustainable eventually disappears. Patients give innovation its purpose. Stewardship is what allows innovation to continue. One without the other leaves the work unfinished.

When I began in this industry I assumed my education would be technical. Finance, commercialization, manufacturing, market access, patient services, the disciplines that together allow a scientific discovery to become something tangible in another person’s life. In many ways that is exactly what happened. What I did not expect was that the longer I stayed, the less the important lessons had to do with the mechanics and the more they had to do with the people inside them. What follows is why the false choice persists, what it costs the organizations that accept it, and what the integrated version looks like when a company actually commits to it.

The false choice, and what it has cost

I want to be fair to where the idea came from. The belief that patient welfare and commercial performance sit at opposite ends of a seesaw did not appear out of nowhere. It grew out of a legitimate concern. Pharmaceutical companies respond to incentives like any commercial enterprise, and there are real, well-documented cases where short-term revenue pressure produced decisions that were not in patients’ interests. Those cases deserve the scrutiny they get, and I would not want to work in an industry where they did not.

But I no longer believe the pullback happens because anyone decided patients matter less. It happens because of how the money is structured, and I have been in the room when it did.

Start with the measurement problem. A patient support program is genuinely difficult to measure, and difficult in a specific way. The return arrives late. It arrives through adherence and persistence rather than through a campaign you can attribute. And it shows up as revenue that was never lost rather than revenue that was gained, which is the hardest kind of result to put in front of a finance committee. So when a budget comes under review, patient support sits in the column of line items that cannot defend themselves with a number.

Then there is where the money actually sits. Commercial does not fund medical affairs. Brand budgets often do, through allocation. A single brand budget can carry opex owned by many different functions, and those owners rarely see one another’s line items. What they share is one brand lead who carries the entire brand P&L. When the totality of that P&L comes under scrutiny, every allocation inside it comes under scrutiny with it, including the ones that were never the brand lead’s idea and are not measured in the brand lead’s terms.

That is the moment the decision actually gets made. Not in a strategy session about patients. In a budget review, by one person accountable for one number, looking at line items that cannot prove themselves.

What makes that costly rather than merely unfortunate is what the room cannot see. If the people making the decision do not share an accurate picture of how the patient journey actually runs, the decision is made in a vacuum. On the page it looks like a reasonable trim of an unprovable expense. In practice it is a decision about whether a particular person gets a returned phone call, finishes an enrollment form, or starts the therapy their clinician already decided they needed. Nobody in that room intended that outcome. Nobody in that room could see it either.

I want to be careful about the conclusion I draw here, because the easy move is to reach for the return on investment, and I think that argument is only half right. Later in this piece I make the commercial case, and I believe every part of it. But the return is not why you fund patient support. You fund it because it is the right thing to do for someone trying to begin a treatment that has already been chosen for them. The return is real. It simply arrives on a timeline, and through pathways, that an allocation model was never built to see. If the only defense of patient support is its measurable return, it will lose the argument in exactly the quarter where losing it costs the most.

How patient outcomes actually reach the income statement

It is worth being precise about the mechanism, because “patient outcomes drive value” is a platitude until you can trace it to a line item. I spent a long time unable to trace it, which is part of why I am careful about it now.

Start with adherence. A therapy with excellent clinical data and poor real-world adherence will underperform its own trial results, sometimes badly, and that gap lands directly in revenue, in payer negotiations and in the credibility of the brand with prescribers. Money spent removing friction from the patient journey protects the clinical investment that got the product to market in the first place.

The same logic runs through prescriber trust. Clinicians are reasonably skeptical of commercial messaging that feels disconnected from what happens to the people in their waiting room. A company that can show, credibly, that its support infrastructure improves real-world outcomes has turned that credibility into a commercial asset. It shows up in formulary conversations, in peer-to-peer education and in who is willing to speak on the company’s behalf. None of it appears on a promotional return spreadsheet, which is exactly why it stays underfunded.

Then there is market access. Payers have become good at telling the difference between a product with genuine value-based outcomes and a product defending share with promotional spend. Real-world outcomes data is leverage in a value-based contracting conversation, and the reimbursement landscape has been moving in that direction for the better part of a decade.

Market access and the profitability equation

Nowhere is the false choice more expensive, or more avoidable, than in market access. Access sits at the intersection of clinical evidence, payer economics and patient affordability, and it is routinely treated as a downstream technical function that happens after the real commercial strategy has been settled. That sequencing is the mistake, because access strategy shapes the economics of the entire product lifecycle from the first day of launch.

A company that builds access around genuine affordability builds a position competitors find hard to erode. Not discounting to move volume. Structurally reducing the financial burden that stops patients from starting or continuing therapy. Payers respond to evidence of real-world value. Patients respond to less friction. Commercial teams that design to that reality rather than to short-term list price optimization find their long-term revenue trajectory steadier than that of competitors chasing quarter-over-quarter increases.

I have walked organizations through exactly this transition, from an access function that is reactive and defensive to one designed around what reaching the therapy actually costs a patient in money and in effort. The gains are not marginal, and they compound. Every patient who starts and stays on therapy is both a clinical result and a durable revenue line, and every barrier removed closes a leak that no amount of promotional spend fully offsets.

Commercial excellence is a patient-centered discipline

In many organizations “commercial excellence” has narrowed to mean sales force effectiveness, targeting algorithms and promotional resource allocation. Those are tools. They are not the discipline.

The discipline starts with an honest account of the patient journey: where patients are lost, why they are lost, and what would have to change to keep them in effective treatment. That reframing changes what gets built. Instead of asking how to get more prescriptions written, the more productive question is why written prescriptions fail to become sustained therapy, and what would close that gap. The second question leads straight into medical affairs collaboration, patient support design and access strategy. Those functions are traditionally walled off from commercial teams, and properly integrated they are the highest-leverage commercial investments available.

The Patients + Profitability™ framework

Across biotech and established pharma I have distilled the integrated approach into four connected pillars. None of them was discovered in a single conversation or a single role. They emerged slowly, through years of listening to people who could see parts of the journey I could not, and each one reinforces the others rather than competing with them for budget.

Journey diagnosis. Before any commercial decision, the organization needs an evidence-based map of the real patient journey. Not the idealized version in a marketing deck. The actual one, with every point of friction, drop-off and delay. Everything downstream rests on this.

Value-aligned access. Access strategy built on demonstrable patient value rather than short-term list price defense, which positions the organization for durable payer relationships and slower price erosion.

Integrated commercial execution. Sales, medical affairs and patient support operating against one shared model of the journey instead of separate departmental targets, which removes both the duplication and the blind spots that siloed execution creates.

Outcome-linked leadership accountability. Incentives and reporting structured so that patient outcome metrics and commercial performance metrics are reviewed together, in the same meeting, by the same people.

The business case for integration

Skeptical commercial leaders are right to ask for the case rather than the philosophy, and I would rather be asked. What follows is why the investment holds up financially. It is still not the reason to make it. It rests on three dynamics that repeat across therapeutic areas and company sizes.

Adherence protects revenue more cheaply than acquisition builds it. Products with above-average adherence beat their launch projections over multi-year horizons far more reliably than products relying on aggressive new-patient acquisition to offset predictable attrition. Chasing new starts gets more expensive every year as competition increases. Protecting existing therapy relationships is comparatively cheap, and it compounds.

Demonstrated value slows price erosion. Payers negotiate harder against products that cannot show real-world outcome value beyond the trial data. Organizations that invest early in outcomes tracking and support infrastructure arrive at renewal with evidence rather than leverage alone, and that shows up in contract terms.

Prescriber trust lowers acquisition cost. When clinicians see consistent evidence that a company’s support infrastructure improves outcomes for their patients, the cost of earning continued prescribing falls. Trust, once earned, is commercially efficient in a way promotional frequency never is.

None of this requires trading margin for goodwill. It requires recognizing that in this industry patient goodwill is margin. Deferred, compounding, and considerably more durable than the alternative.

Leadership in an age of dual accountability

None of this happens without deliberate leadership. Frameworks and org charts do not integrate themselves. Someone has to make the explicit and occasionally uncomfortable decision to hold commercial and clinical teams accountable to a shared definition of success rather than letting each function optimize its own narrow measure.

It is one of the harder transitions in the industry, because it usually means restructuring incentive plans, changing how success is reported to boards and investors, and building cross-functional reporting lines that did not previously exist. Letting commercial chase the quarter while medical affairs pursues scientific rigor in parallel, each unaware of how it affects the other, is far easier in the short term. Easier in the short term is precisely the trap that produces the false choice this piece opened with.

The leaders who make the transition tend to share a few habits. They ask for patient journey data in the same meeting where they review commercial performance rather than in a separate quarterly review. They judge a launch on both the clinical adoption curve and the patient retention curve, and treat the second as no less important than the first. And they are willing to bring in an outside read, because the silos that need dismantling are usually held in place by internal history that insiders cannot see around.

What this adds up to

The companies that define the next decade will not be the ones that resolve the tension between patients and profitability by picking a side. They will be the ones that recognize the tension was never as real as it looked. It was a symptom of organizational fragmentation, not an inherent conflict between two legitimate goals.

Patients + Profitability™ is not an argument for less commercial rigor. It is an argument for pointing that rigor at the right target: a patient journey healthy enough, and frictionless enough, that profitability follows from doing the work well rather than competing with it.

The enterprise develops, manufactures, prices, contracts, distributes and supports. It does not diagnose, prescribe, dispense or treat. Within that boundary there is a great deal it can control, and most of it is currently being measured by someone who is not looking at the patient.

I did not arrive at any of this on my own. I learned it from researchers who spent decades pursuing answers that did not yet exist, from physicians carrying conversations no family hopes to have, and from nurses, pharmacists, patient advocates, manufacturing and finance colleagues who each accepted responsibility for one small part of a journey none of us could see in full. Behind every process, every meeting, every forecast and every operational decision was another person hoping to get back to the life they had.

So my hope for this is not that you agree with every conclusion in it. It is that you start asking your own questions about where your organization loses people, and what it costs when it does. Every one of us is building some part of a path that someone else has to cross.

Frequently asked questions

What does Patients + Profitability™ mean in practice?

It means designing commercial strategy, market access and medical affairs collaboration around one shared model of the patient journey, rather than treating patient outcomes and commercial performance as separate priorities owned by separate teams with separate metrics.

Is focusing on patient outcomes a real strategy or just good messaging?

It can be either, and execution is what separates them. The test is whether patient outcome data actually changes commercial decisions such as targeting, access strategy and resource allocation, or whether it lives in a communications narrative disconnected from how the business runs.

How does this apply differently to a first-launch biotech than to an established company?

A biotech gets to build its commercial and medical infrastructure without legacy silos to dismantle, but often without the resources for extensive patient support at launch. An established company has the resources and has to actively work against the fragmentation it already carries.

What is the biggest barrier to integrating patient outcomes into commercial strategy?

Usually not belief. Usually incentives. When commercial leaders are measured on quarterly prescription volume and medical affairs leaders are measured on scientific engagement, neither has an organizational reason to collaborate no matter how much they personally agree with the idea.

How is this different from a value-based healthcare framework?

Value-based healthcare frameworks are mostly about payer and provider reimbursement models. Patients + Profitability™ is a commercial and organizational operating framework spanning the full patient journey, including access, medical affairs collaboration and commercial execution. Value-based principles are one input to it rather than the whole strategy.

Where should a leader start?

With an honest patient journey diagnosis. Identify exactly where patients disengage from therapy and why, before making any further structural or strategic decision. That diagnosis is the shared foundation the commercial and clinical teams can then build from together.

The patterns described here reflect my own experience advising pharmaceutical and biotech organizations, and are offered as commentary rather than as legal, regulatory, clinical or accounting advice. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.